European law firm Fieldfisher has advised AIM-quoted Synairgen plc, a leading respiratory disease drug discovery company based in Southampton, on its £87 million fundraising to begin the Phase III trial for a potential inhaled treatment for COVID-19
NanoSyrinx is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism. The company will focus on direct cytosolic delivery of genome editing enzymes and therapeutic proteins in vivo, with key applications in the cell and gene therapy space.
The UK Government grant will support new and existing projects until March 2022. Funding will ensure that the positive impact of the ATTC network continues; further optimising the UK ecosystem for routine adoption of advanced therapies.
AskBio announces the award of a £1.99m R&D Grant from Scottish Enterprise. AskBio will invest £3.4m alongside the grant to fund research into the manufacturing challenges associated with scaling gene therapies for widespread patient access, to further develop technologies to improve the safety and efficacy of current therapies, and to enable the treatment of genetic diseases with more complicated disease pathways that the industry is not yet able to address.